14 Cathie Wood Fate Therapeutics Trades
The first Fate Therapeutics trade was made in Q4 2019. Since then Cathie Wood bought shares ten more times and sold shares on three occasions. The investor completely sold their stake between Q4 2022 and Q1 2023.
Avg closing price
Price range
Sold -4.21 Million shares
Q1 2023
Avg closing price
$6.03
Price range
$4.24
-
$11.12
Sold 63.8% shares (-7.44 Million shares)
Q4 2022
Avg closing price
$18.78
Price range
$9.86
-
$23.83
Increased shares by 1.6% (+182 Thousand shares)
Q3 2022
Avg closing price
$28.89
Price range
$21.04
-
$36.06
Increased shares by 4.4% (+485 Thousand shares)
Q2 2022
Avg closing price
$27.59
Price range
$17.78
-
$42.39
Increased shares by 6.6% (+676 Thousand shares)
Q1 2022
Avg closing price
$38.72
Price range
$29.67
-
$60.28
Sold 5.4% shares (-590 Thousand shares)
Q4 2021
Avg closing price
$56.68
Price range
$47.84
-
$64.34
Increased shares by 45.7% (+3.42 Million shares)
Q3 2021
Avg closing price
$78.44
Price range
$59.27
-
$95.73
Increased shares by 14.2% (+929 Thousand shares)
Q2 2021
Avg closing price
$80.58
Price range
$67.25
-
$92.52
Increased shares by 125.9% (+3.65 Million shares)
Q1 2021
Avg closing price
$95.82
Price range
$72.16
-
$117.40
Increased shares by 101.5% (+1.46 Million shares)
Q4 2020
Avg closing price
$62.10
Price range
$38.09
-
$100.95
Increased shares by 41.2% (+420 Thousand shares)
Q3 2020
Avg closing price
$34.92
Price range
$30.41
-
$40.50
Increased shares by 83.7% (+465 Thousand shares)
Q2 2020
Avg closing price
$29.80
Price range
$20.21
-
$35.23
Increased shares by 28.8% (+124 Thousand shares)
Q1 2020
Avg closing price
$25.29
Price range
$17.28
-
$31.88
New holding (+431 Thousand shares)
Q4 2019
Avg closing price
$15.88
Price range
$13.39
-
$20.73
News about Fate Therapeutics Inc and Cathie Wood
Cathie Wood Is Buying Up Red-Hot Fate Therapeutics (FATE) Stock
Source: ra2 studio/Shutterstock Shares of Fate Therapeutics (NASDAQ: FATE ) stock are up 3% following a massive purchase by two of Cathie Wood’s exchange-tra...
Recent Poor Results Have Made This Promising Cathie Wood Pick a Bargain
Positive news versus poor clinical trial results may determine the future of Fate Therapeutics.